CC BY-NC-ND 4.0 · Neurology International Open 2018; 2(02): E84-E92
DOI: 10.1055/s-0043-124983
Eigentümer und Copyright ©Georg Thieme Verlag KG 2018

Treatment Standards and Individualized Therapy of Myasthenia Gravis

Peter Paul Urban
Neurologische Klinik, Asklepios Klinik Barmbek, Hamburg
Christian Jacobi
Neurologische Klinik, Krankenhaus Nordwest GmbH, Frankfurt am Main
Sebastian Jander
Klinik für Neurologie, Universitätsklinikum Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
03 April 2018 (online)


A wide range of established treatment options is currently available for myasthenia gravis. These include cholinesterase inhibitors for symptomatic treatment and a broad spectrum of immunosuppressive, immunomodulating or cell-depleting options to modify the underlying immunological process. Appropriate use allows the great majority of patients to lead a normal life. Specialized centers integrating outpatient and in-hospital resources as well as interdisciplinary competences offer important advantages for optimum individualized therapy.